問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

許朝偉Hsu, Chao-Wei
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years 1 個月

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許朝偉

List

53Cases

2005-10-01 - 2007-09-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2026-01-01 - 2032-03-10

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting7Sites

2024-12-01 - 2029-03-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2016-11-01 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated11Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2014-04-20 - 2016-05-20

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-02-01 - 2028-01-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2010-08-01 - 2014-12-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-06-01 - 2023-06-28

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Terminated3Sites

2009-03-03 - 2016-03-03

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2019-10-01 - 2020-12-30

Phase II

A Phase 2a open-label study of the oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect in chronic Hepatitis B (CHB) patients in combination with pegylated interferon alpha2a (peg-IFN) alone and with entecavir (ETV)

  • Condition/Disease

    chronic Hepatitis B

  • Test Drug

    EYP001a

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB